THE Therapeutic Goods Administration (TGA) has approved Australia's first respiratory biologic medicine with an eight-week dosing schedule, following initiation with three doses administered every 4-weeks for severe eosinophilic asthma.
Fasenra (benralizumab) from AstraZeneca (AZ) has been registered as an add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count 300 cells/L or 150 cells/L if on oral corticosteroid treatment).
AZ will provide early access via a Product Familiarisation Program for qualifying specialists.
The Schedule 4 entry in the Poisons Standard takes effect 01 Jun 2018 - see the PI at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 May 18